



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

April 5, 2024

Carmine Stengone  
Chief Executive Officer and President  
Contineum Therapeutics, Inc.  
10578 Science Center Drive, Suite 200  
San Diego, California 92121

**Re: Contineum Therapeutics, Inc.**  
**Form S-1**  
**Exhibit No. 10.16**  
**Filed March 15, 2024**  
**File No. 333-278003**

Dear Carmine Stengone:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Jeffrey Thacker, Esq.